Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Change in Cash (2016 - 2025)

Historic Change in Cash for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $244000.0.

  • Northwest Biotherapeutics' Change in Cash rose 32068.97% to $244000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 15133.0%. This contributed to the annual value of $49000.0 for FY2024, which is 10101.26% up from last year.
  • Northwest Biotherapeutics' Change in Cash amounted to $244000.0 in Q3 2025, which was up 32068.97% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Change in Cash peaked at $11.3 million during Q4 2021, and registered a low of -$8.2 million during Q1 2022.
  • For the 5-year period, Northwest Biotherapeutics' Change in Cash averaged around -$285421.1, with its median value being $58000.0 (2024).
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 74158.16% in 2021, then skyrocketed by 578974.36% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Change in Cash (Quarter) stood at $11.3 million in 2021, then tumbled by 121.71% to -$2.5 million in 2022, then plummeted by 61.42% to -$4.0 million in 2023, then soared by 80.76% to -$764000.0 in 2024, then skyrocketed by 131.94% to $244000.0 in 2025.
  • Its last three reported values are $244000.0 in Q3 2025, $1.5 million for Q2 2025, and $604000.0 during Q1 2025.